Skip to content
Home/Companies/Healthcare/Jasper Therapeutics

Jasper Therapeutics

Healthcare·US·Exited 2021·Held 2yr
Entry
2019
Hold
2yr
Exit
2021

Who owns Jasper Therapeutics?

Jasper Therapeutics was owned by Abingworth through Abingworth Bioventures VII (2018 vintage) from 2019 to 2021, exited via IPO.

Buyer identity available on Pro.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures VII · 2018 · Life Sciences VC

Key facts

HQUS
SectorHealthcare
StatusActive
Exit Type
IPO
Buyer
MOIC
–
Exit Year
2021

More from Abingworth Bioventures VII

Other portfolio companies in the same fund.

Adicet Bio
Adicet Bio
Active
BiotechUS· 2021
Soteria Biotherapeutics
Soteria Biotherapeutics
Active
HealthcareUS· 2021
Atsena Therapeutics
Atsena Therapeutics
Active
BiotechUS· 2020
Orbus Therapeutics
Orbus Therapeutics
Active
HealthcareUS· 2020
Q32 Bio
Exited 2024
BiotechUS· 2020
Scorpion Therapeutics
Scorpion Therapeutics
Exited 2025
BiotechUS· 2020
to

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
A Place for Mom
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Track Jasper Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Jasper Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue